Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation

被引:15
|
作者
Chaussade, E. [1 ,2 ]
Hanon, O. [1 ,2 ]
Boully, C. [1 ,2 ]
Labouree, F. [1 ,2 ]
Caillard, L. [1 ,2 ]
Gerotziafas, G. [3 ,4 ]
Vidal, J. -S. [1 ,2 ]
Elalamy, I. [3 ,4 ]
机构
[1] Hop Broca, AP HP, Paris, France
[2] Univ Paris 05, Sorbonne Paris Cite, Equipe Accueil 4468, Paris, France
[3] Hop Tenon, HUEP, AP HP, Serv Hematol Biol, Paris, France
[4] UPMC Paris 6, UMR S 938, Paris, France
关键词
Anticoagulants; antithrombins; atrial fibrillation; aged; 80 and over; ORAL ANTICOAGULANTS; ELDERLY-PATIENTS; ANTITHROMBOTIC THERAPY; COAGULATION ASSAYS; DRUG-THERAPY; RISK; WARFARIN; STROKE; PHARMACOKINETICS; METAANALYSIS;
D O I
10.1007/s12603-017-0982-4
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Few geriatric patients were included in studies on direct oral anticoagulants and data on dabigatran concentration and safety are needed in this population. Our objectives were to evaluate peak and trough dabigatran plasma concentrations over time in a geriatric population and to identify factors associated with dabigatran plasma concentrations and to assess the relationship with bleeding events. Peak and trough dabigatran plasma concentration were performed 4,8,15,30,45 days after inception of dabigatran treatment in 68 consecutive patientsae<yen>75 years old hospitalized in a geriatric hospital with atrial fibrillation. Bleeding events were monitored for 1 year. Mean age was 85.8(5.1) years old and 76.5% were women. Overall, 541 dabigatran plasma measurements (270 peak, 271 trough) were performed. Mean dabigatran concentrations of the 5 sequential measurements ranged 106-146ng/mL for peak and 66-84ng/mL for trough. Renal failure was associated with high peak and trough dabigatran concentration. Inter- and intra-individual coefficients of variation were 59.5% and 44.7% for peak and 74.5% and 44.6% for trough. Participants in the lower two tertiles of dabigatran concentration at day 8 (D8) remained below the 90(th) percentile (243.9ng/ml) on the next measurements. Bleeding events were associated with high trough dabigatran concentrations. Trough dabigatran concentration at D8 > 243.9ng/mL significantly predicted bleeding. In this geriatric population, renal function and low albumin were associated with dabigatran concentrations. Despite large variability, participants in the lower two tertiles of dabigatran concentration at D8 remained below the 90(th) percentile on the following measurements. D8 dabigatran trough concentrationae<yen>243.9ng/mL identified patients at risk of bleeding.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 50 条
  • [1] Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation
    E. Chaussade
    Olivier Hanon
    C. Boully
    F. Labourée
    L. Caillard
    G. Gerotziafas
    J.-S. Vidal
    I. Elalamy
    The journal of nutrition, health & aging, 2018, 22 : 165 - 173
  • [2] Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience
    Mumoli, Nicola
    Mastroiacovo, Daniela
    Tamborini-Permunian, Eleonora
    Vitale, Jose
    Giorgi-Pierfranceschi, Matteo
    Cei, Marco
    Dentali, Francesco
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2017, 18 (07) : 467 - 477
  • [3] On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation
    Skeppholm, Mika
    Hjemdahl, Paul
    Antovic, Jovan P.
    Muhrbeck, Josephine
    Eintrei, Jaak
    Ronquist-Nii, Yuko
    Pohanka, Anton
    Beck, Olof
    Malmstrom, Rickard E.
    THROMBOSIS RESEARCH, 2014, 134 (04) : 783 - 789
  • [4] Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study
    Balsam, Pawel
    Ozieranski, Krzysztof
    Tyminska, Agata
    Zukowska, Katarzyna
    Zaleska, Martyna
    Szepietowska, Katarzyna
    Macieiewski, Kacper
    Peller, Michal
    Grabowski, Marcin
    Lodzinski, Piotr
    Praska-Oginska, Anna
    Zaboyska, Inna
    Koltowski, Lukasz
    Kowalczuk, Anna
    Bednarski, Janusz
    Filipiak, Krzysztof J.
    Opolski, Grzegorz
    KARDIOLOGIA POLSKA, 2018, 76 (05) : 889 - 898
  • [5] Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillationl
    Sinigoj, Petra
    Malmstrom, Rickard E.
    Vene, Nina
    Roenquist-Nii, Yuko
    Bozic-Mijovski, Mojca
    Pohanka, Anton
    Antovic, Jovan P.
    Mavri, Alenka
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 (05) : 323 - 329
  • [6] Antithrombotic treatment in real-life atrial fibrillation patients:: a report from the Euro Heart Survey on Atrial Fibrillation
    Nieuwlaat, Robby
    Capucci, Alessandro
    Lip, Gregory Y. H.
    Olsson, S. Bertil
    Prins, Martin H.
    Nieman, Fred H.
    Lopez-Sendon, Jose
    Vardas, Panos E.
    Aliot, Etienne
    Santini, Massimo
    Crijns, Harry J. G. M.
    EUROPEAN HEART JOURNAL, 2006, 27 (24) : 3018 - 3026
  • [7] Clinical characteristics, adherence to anticoagulation therapy and prognosis in patients with atrial fibrillation: a real-life study
    Qi, Fenglin
    Wu, JiaCan
    Xia, Zhen
    Xie, Siyuan
    Chen, Xianya
    Zheng, Huanjie
    Li, Zhuo
    Bao, Naiyue
    Li, Chengcheng
    Xiao, Hua
    BMC CARDIOVASCULAR DISORDERS, 2025, 25 (01):
  • [8] Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease
    Skripka, Alena
    Sychev, Dmitriy
    Bochkov, Pavel
    Shevchenko, Roman
    Krupenin, Pavel
    Kogay, Veronika
    Listratov, Alexander
    Krainyaya, Arina
    Gurinovich, Olga
    Sokolova, Anastasiya
    Napalkov, Dmitry
    Fomin, Viktor
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2020, 27 (02) : 151 - 156
  • [9] Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease
    Alena Skripka
    Dmitriy Sychev
    Pavel Bochkov
    Roman Shevchenko
    Pavel Krupenin
    Veronika Kogay
    Alexander Listratov
    Arina Krainyaya
    Olga Gurinovich
    Anastasiya Sokolova
    Dmitry Napalkov
    Viktor Fomin
    High Blood Pressure & Cardiovascular Prevention, 2020, 27 : 151 - 156
  • [10] Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation
    Baron-Esquivias, Gonzalo
    Fernandez-Aviles, Francisco
    Atienza, Felipe
    Pastor Pueyo, Pablo
    Toro, Rocio
    Sanmartin Fernandez, Marcelo
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (04) : 341 - 353